Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL750515 | 0.89 | HSD17B10 (0.50) | HSD17B10ROCK2SMN1; SMN2FKBP1A | |
| SCHEMBL11932167 | 0.89 | HSD17B10 (0.50) | HSD17B10ROCK2SMN1; SMN2FKBP1A | |
| SCHEMBL4154856 | 0.88 | FKBP1A (0.47) | HSD17B10ROCK2HPGDSMN1; SMN2FKBP1A | |
| SCHEMBL540702 | 0.88 | FKBP1A (0.47) | HSD17B10ROCK2HPGDSMN1; SMN2FKBP1A | |
| SCHEMBL5517111 | 0.88 | FKBP1A (0.47) | HSD17B10ROCK2HPGDSMN1; SMN2FKBP1A | |
| SCHEMBL7328713 | 0.85 | HSD17B10 (0.49) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL27410636 | 0.84 | HSD17B10 (0.52) | HSD17B10ROCK2PREPSMN1; SMN2FKBP1A | |
| SCHEMBL27761053 | 0.81 | SMN1; SMN2 (0.34) | HSD17B10HRH3CHRM2CHRM1CHRM3 | |
| SCHEMBL9949884 | 0.80 | CHRM2 (0.38) | HSD17B10HRH3MAPK1CHRM2CHRM1 | |
| SCHEMBL22152560 | 0.80 | HRH3 (0.35) | HSD17B10HRH3MAPK1CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250232-A1 | AZETIDINE DERIVATIVES AND USE THEREOF AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-08-07 | — | — | US | disclosed |
| WO-2024008680-A1 | AZETIDINE DERIVATIVES AND USE THEREOF AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-01-11 | — | — | WO | disclosed |
| US-6927290-B2 | Production of mixed acid anhydride and amide compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-08-09 | — | — | US | disclosed |
| EP-1160236-B1 | Production of mixed acid anhydride and amine compound | SUMITOMO CHEMICAL CO (JP) | 2005-05-25 | — | — | EP | disclosed |
| US-20040210059-A1 | Production of mixed acid anhydride and amide compound | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-10-21 | — | — | US | disclosed |
| US-6753431-B2 | REACTING A CARBAMATE DERIVATIVE WITH CARBOXYLIC AND HALOFORMIC ACID DERIVATIVES | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2004-06-22 | — | — | US | disclosed |
| US-20020032346-A1 | Production of mixed acid anhydride and amide compound | SUMITOMO CHEMICAL CO., LTD. | 2002-03-14 | — | — | US | disclosed |
| EP-1160236-A2 | Production of mixed acid anhydride and amine compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-12-05 | — | — | EP | disclosed |
| WO-2001034150-A1 | ALIPHATIC AMINE SUBSTITUTED PIPERIDYL DIARYL PYRROLE DERIVATIVES AS ANTIPROTOZOAL AGENTS | MERCK & CO., INC. (US) | 2001-05-17 | — | — | WO | disclosed |
| EP-1089989-A1 | INHIBITORS OF ALPHA4BETA1 MEDIATED CELL ADHESION | PHARMACIA & UPJOHN COMPANY (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067230-A1 | INHIBITORS OF α4β1 MEDIATED CELL ADHESION | PHARMACIA & UPJOHN COMPANY (US) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040210059-A1 | Production of mixed acid anhydride and amide compound | CA2, CA1, CA3 | HSD17B10 2385/4885HRH3 330/4885MAPK1 1266/4885 |
| US-20020032346-A1 | Production of mixed acid anhydride and amide compound | CA2, CA1, CA3 | HSD17B10 2385/4885HRH3 330/4885MAPK1 1266/4885 |
| US-20250250232-A1 | AZETIDINE DERIVATIVES AND USE THEREOF AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS | DPP9, DPP4, DPP3 | HSD17B10 2261/4885HRH3 1772/4885MAPK1 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.